<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Remake of Sarah 2pm Week 3 HNN215 Week 3 Padlet  by </title>
      <link>https://padlet.com/sarahd59/18qal72y627oqa68</link>
      <description>Management of patients experiencing cardiovascular symptoms (1)</description>
      <language>en-us</language>
      <pubDate>2023-03-16 09:13:30 UTC</pubDate>
      <lastBuildDate>2023-04-05 02:29:49 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Significant drug-drug interactions???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086004</link>
         <description><![CDATA[<div>How / why does it occur?<br>What are they and what signs and symptoms would we see?<br>What do we as nurses do;<br>- prevent and/ or manage these?</div>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/0d9bb351cd19e88a6d7fd4581ea11801/image.png" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086004</guid>
      </item>
      <item>
         <title>Case Scenario</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086005</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/5166acda6816da77382de126b6cb12b7/image.png" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086005</guid>
      </item>
      <item>
         <title>Compare and contrast the significant risks for each of the drug classes</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086006</link>
         <description><![CDATA[<div>What were your significant risks? Why are they significant?<br>Do you understand the MoA of how the patient might develop the risk?<br>Did you need to go and look them up again?&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086006</guid>
      </item>
      <item>
         <title>Scenario continued</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086007</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/d54ee1da52c05161e784012bb7e0b266/image.png" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086007</guid>
      </item>
      <item>
         <title>Part 2???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086008</link>
         <description><![CDATA[<div>This will be added once we get to it :)</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086008</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086009</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/35630b4b43ddbe61fe512dcfc206488d/HNN215_week_3_NIMC_2023.pdf" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086009</guid>
      </item>
      <item>
         <title>Consider???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086010</link>
         <description><![CDATA[<div><strong><mark>Note: Always consider:<br>Is there anything in the patient's condition/ past history that may increase the risks?</mark></strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086010</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086011</link>
         <description><![CDATA[<div>Temazepam<br><br>MOA:&nbsp;<br>Benzodiazepines potentiate the inhibitory effects of GABA throughout the CNS, resulting in anxiolytic, sedative, hypnotic, muscle relaxant and antiepileptic effects.<br><br></div><div>Indications for use: Short-term treatment for Insomnia</div><div><br>Nursing considerations: Consideration of the pts. vital signs (RR) since it causes respiratory depression.&nbsp;<br>- Increased risk of oversedation, falls, memory, confusion, ataxia due to the pat being on the elderly side.<br><br>Drug/Drug interaction: Metabolism of temazepam can be decreased when combined with Amiodarone&nbsp;<br><br>Signs and Symptoms:&nbsp;Drowsiness, over-sedation, headache, hypotension, respiratory depression, confusion.</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086011</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086012</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/056c36e613ef99f18d9d091b6e0e0211/IV_Orders_week_3_2023.pdf" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086012</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086013</link>
         <description><![CDATA[<div>the benefits of a loading dose is that is gets the drug to a therapeutic range quicker then what normal dosing of a drug does.&nbsp;<br>as amiodarone medication can take longer time periods to reach therapeutic levels a loading dose gets the drug to work quickly and effectively (orally).&nbsp;<br>IV amiodarone&nbsp;<br>Loading, IV 5 mg/kg over 20 minutes – 2 hours.<br>Maintenance, IV 15–20 mg/kg over 24 hours (maximum 1.2 g in 24 hours); begin oral treatment as soon as possible, overlapping oral and IV treatment by up to 2 days.<br><br></div><div><br></div><div><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086013</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086014</link>
         <description><![CDATA[<div>Amiodarone<br><br>MOA:&nbsp;<br>Decreases sinus node and junctional automaticity, slows atrioventricular (AV) and bypass tract conduction and prolongs refractory period of myocardial tissues (atria, ventricles, AV node and bypass tract); also has weak beta-blocker activity.<br><br>Indications:&nbsp;<br>Treatment and prophylaxis of serious tachyarrhythmias refractory to other treatment, including ventricular tachycardia, AF and SVT<br><br>Nursing considerations:<br>- Check patient allergies<br>- Understand their baseline vital sign readings<br>- You'll want to monitor the EKG continuously during IV amiodarone infusion and initiation of PO therapy. Amiodarone can cause pulmonary toxicity and ARDS, so monitor your patient's respiratory status carefully. Patients taking amiodarone long-term should get regular chest x-rays and pulmonary function tests.<br><br>Drug-drug interactions:&nbsp;</div><div>- Amiodarone has a very long half-life and it may take weeks to months before an interaction fully develops; when it is stopped interactions may continue for weeks to months.<br><br>- Amiodarone may increase <strong><em>metoprolol’s</em></strong> concentration, increasing the risk of severe bradycardia; consider using a low dose to start metoprolol treatment, and monitor carefully.<br><br></div><div><br>Signs and symptoms:<br>- nausea &amp; vomiting<br>- constipation<br>- anorexia<br>-</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086014</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086015</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086015</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086016</link>
         <description><![CDATA[<div>Metoprolol<br><br>MOA:<br>Metoprolol is a cardioselective beta-1-adrenergic receptor inhibitor that competitively blocks beta1-receptors with minimal or no effects on beta-2 receptors at oral doses of less than 100 mg in adults. It decreases cardiac output by negative inotropic and chronotropic effects.<br><br>Indications for use:<br>- High blood pressure<br>- Chest pain due to reduced blood flow to the heart (Angina)<br>- Tachyaahythmias&nbsp;<br>- Prevention of migraine&nbsp;<br>- Chronic heart failure&nbsp;<br><br>Nursing considerations:&nbsp;<br>- Monitoring blood pressure&nbsp;<br>- Assess hypersensitivity&nbsp;<br>- Monitor for side effects&nbsp;<br><br>Signs and Symptoms:<br>- Bradycardia<br>- Hypotension<br>- Worsening of heart failure<br>- Nausea<br>- Diarrhoea&nbsp;<br>- Bronchospasm<br>- Dyspnoea<br>- Cold extremitites&nbsp;<br>- Fatigue&nbsp;<br>- Dizziness&nbsp;<br>- Abnormal vision<br>- Alteration of glucose&nbsp;<br>- Hallucinations<br>- Insomnia<br>- Nightmares<br>- Heart block<br>- Rash<br>- Muscle cramp<br>- Nasal congestion&nbsp;<br>- Hypersensitivity reaction&nbsp;<br><br>Drug-Drug interactions<br>Lidocaine and Metoprolol= Metoprolol may reduce metabolism and increase risk of toxicity of lidocaine when it is used IV&nbsp;<br>Amiodarone and Metoprolol= Amiodarone may increase metoprolos concentration, increasing the risk of severe bradycardia </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086016</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086017</link>
         <description><![CDATA[<div>Due to the drugs nature of a long half life, initiating a loading dose in the beginning helps to achieve the therapeutic levels on the first dose, then maintenance to achieve these therapeutic levels can be achieved following. </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086017</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086018</link>
         <description><![CDATA[<div>Amlodipine<br><br>MOA: act on coronary arteriolar smooth muscle to reduce vascular resistance and myocardial oxygen requirements, relieving angina symptoms. The blockage of calcium channels inhibits the influx of calcium ions in, the cell reducing depolarization of myocardial cells and reduction of myocardial contraction, due to its association with actin and myosin stimulation.&nbsp;<br><br>Indications: hypertension, angina<br><br>Nursing considerations: ECG, vitals - BP, HR, due to vasodilation of blood vessels can cause headaches, pain levels of patient<br><br>Signs and Symptoms: respiratory depression, vasodilatory effects, hypotension, nausea/vomiting, peripheral oedema&nbsp;<br><br>Drug-drug interaction:&nbsp;<br>magnesium - increases the effects of IV magnesium sulphate and the risk of adverse effects&nbsp;<br>enoxaparin - increases the toxicity of amlodipine</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086018</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086019</link>
         <description><![CDATA[<div>A loading does is a higher dose/quicker administration of a drug that may be given at the start of a course of treatment before dropping down to a lower maintenance dose. a loading dose is mainly used for drugs that are eliminated from the body slowly. drugs only need a lower or regular dose to maintain the therapeutic level.&nbsp;<br><br>We would give a loading dose of amiodarone so we can control and lower his heart rate back to sinus rhythm as quick as possible and then continue with the infusion to help sustain regularity in heart rhythm </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086019</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086020</link>
         <description><![CDATA[<div>Potassium/Magnesium&nbsp;<br><br>MOA:<br><br>Indications for use:<br><br>Nursing considerations:<br><br>Drug-drug interactions:<br><br>Signs and Symptoms:</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086020</guid>
      </item>
      <item>
         <title>Loading doses</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086021</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/54fa041d2259ad9b5ea84dd72d734137/image.png" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086021</guid>
      </item>
      <item>
         <title>Additional considerations</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086024</link>
         <description><![CDATA[<div>Something to consider : do we need to think about the patient's underlying condition such as renal function/ liver function when giving a loading dose? Or body weight? If so why??</div>]]></description>
         <enclosure url="http://image.slideserve.com/275846/loading-dose-l.jpg" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086024</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086025</link>
         <description><![CDATA[<div>Slow and wide distribution of amiodarone to tissue (fat, muscle, highly perfused organs) results in a requirement of long loading periods in an effort to accelerate the onset of drug activity. </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-03-16 09:13:30 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/18qal72y627oqa68/wish/2519086025</guid>
      </item>
   </channel>
</rss>
